Acclaimed healthcare executive joins Axena Health’s board to help drive innovation in women’s pelvic health
Erica Rogers Joins the Board of Directors at Axena Health, Bringing Proven Commercial Leadership and Expertise in Groundbreaking Healthcare Solutions
Media:
Shanti Skiffington
617-921-0808
Axena Health, Inc. (Axena Health), a medical device company focused on female pelvic health, today announced the appointment of Erica Rogers to its Board of Directors. Known for her transformative leadership in the medical device industry, Rogers brings over two decades of expertise, including her tenure as President and CEO of Silk Road Medical, where she guided the company from early stages throug h its IPO and commercial expansion, pioneering advancements in stroke prevention.
Roger’s extensive experience leading strong organic growth and operational excellence within commercial-stage medical device businesses aligns well with Axena Health’s commitment to addressing the unique needs of women with pelvic health disorders. At Silk Road Medical, she led innovations in minimally invasive technologies, revolutionizing treatment pathways for vascular care and setting new standards in clinical outcomes. Her background in commercial execution, strategic planning, regulatory affairs and reimbursement will be invaluable to Axena Health as it continues to transform the standard of care in female pelvic health.
“We are thrilled to welcome Erica to our Board of Directors,” said Randy Pritchard, CEO of Axena Health. “Her impressive experience in advancing medical devices from concept to widespread adoption will be critical as we expand the business. Erica’s leadership will help guide us as we provide accessible, clinically proven treatments that provide improved outcomes and greater access to care.”
Rogers commented on her appointment, saying, “I’ve followed the female pelvic health space for years and am excited to join Axena Health because of its unwavering dedication to redefining what’s possible through evidence-based innovation. It’s rare to see such a robust commitment to both patient needs and rigorous clinical data, and I look forward to contributing to a future where Axena’s Leva® Pelvic Health System can provide improved care and quality of life for women everywhere.”
Roger’s addition to the Board underscores Axena Health’s dedication to advancing women’s pelvic health through innovative solutions. Her guidance is expected to play a significant role as the company scales its flagship product, the Leva® Pelvic Health System, and explores new opportunities for growth and impact in the field of women’s health.
About the Leva® Pelvic Health System
The Leva® Pelvic Health System offers an innovative, non-invasive, medication-free way for women to train and strengthen their pelvic floor muscles—at home in just five minutes a day—to treat urinary incontinence (UI) and chronic fecal incontinence (FI). Combining a small FDA-cleared vaginal motion sensor with integrated software, the Leva System offers precise visualization of pelvic movement in real-time, enables progress tracking and allows active physician involvement, all of which support women’s success. Recognizing that level-one evidence shows pelvic floor muscle training is most effective when performed under the supervision of a skilled healthcare provider, the Leva System is available by prescription only, allowing physicians the opportunity to treat UI and chronic FI on a broad scale and with continued involvement in patient success. The Leva System has multiple clinical trials and published data from globally recognized medical centers supporting its efficacy in treating UI, including two studies in Obstetrics and Gynecology (The Green Journal), the official publication of the American College of Obstetricians and Gynecologists (ACOG).
About Axena Health
Axena Health, Inc. is dedicated to improving the lives of women with pelvic floor disorders. Axena Health’s flagship product, the Leva® Pelvic Health System, offers a novel, effective, first-line treatment for urinary incontinence (UI) and chronic fecal incontinence (FI), underreported conditions affecting over 78 million and 12 million women in the U.S. alone. Axena Health's technology enables non-invasive, drug-free treatment via precise visualization of movement in real time during pelvic floor muscle training, while monitoring usage and progress. For more information, please visit www.axenahealth.com or www.levatherapy.com and follow Axena Health on LinkedIn.
Important Indication and Other Information for the Leva® Pelvic Health System
The Leva® Pelvic Health System is intended for (1) strengthening of pelvic floor muscles, (2) rehabilitation and training of weak pelvic floor muscles for the treatment of stress, mixed, and mild to moderate urgency urinary incontinence (including overactive bladder) in women and (3) rehabilitation and training of weak pelvic floor muscles for the first-line treatment of chronic fecal incontinence (>3-month uncontrolled passage of feces) in women. Treatment with the Leva System is by prescription and is not for everyone. Please talk to your prescriber to see if Leva System is right for you. Your prescriber should discuss all potential benefits and risks with you. Do not use Leva System while pregnant, or if you think you may be pregnant, unless authorized by your doctor. For a complete summary of the risks and instructions for the Leva System, see its Instructions for Use available at www.levatherapy.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241119812886/en/
